logo-loader

Scancell focuses on development of two critical cancer fighting assets

Last updated: 08:46 26 Mar 2024 EDT, First published: 01:47 15 Sep 2023 EDT

Snapshot

  • Scancell Holdings doses first patient with iSCIB1+
  • Scancell: US investment bank resumes coverage with punchy price target
  • Scancell CEO hails "exciting" high response rate to melanoma treatment
lab worker

About the company

Scancell Holdings PLC is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer and infectious disease.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells.

In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.

How it is doing

26 Mar 2024

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a developer of immunotherapies for cancer and infectious diseases, has reached a pivotal milestone in its clinical development with the commencement of treatment of the first patient with its new therapeutic, iSCIB1+.

The Scancell discovery will be administered in combination with a doublet checkpoint inhibitor therapy in the SCOPE trial. So, they will receive also receive ipilimumab (Yervoy) and nivolumab (Opdivo), two drugs known for their effectiveness in cancer treatment.

Professor Lindy Durrant, chief executive, said: "As we have previously communicated, we anticipate that iSCIB1+ will be as effective as SCIB1 and could be a promising candidate for registration studies."

iSCIB1+ is an enhanced version of SCIB1, developed through Scancell's AvidiMab platform to increase its effectiveness.

05 Feb 2024

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), the developer of cancer immunotherapies, has announced key changes to its executive team. 

Investors were told Dr Sally Adams is set to retire as chief development officer to be succeeded by Dr Callum Scott, who will assume the role of head of development with immediate effect.

30 Jan 2024

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said it is hoping to build on the significant clinical progress it has made in the first half of the financial year as it set out its "key near-term milestones".

Chief among them will be the second stage of the SCOPE study in advanced melanoma with its key asset, the oncology vaccine SCIB1. Recruitment is slated to start in the first quarter of 2024 meaning data should be available in Q3 of the calendar year.

What the brokers say

04 Jan 2024

Stifel has resumed coverage of biopharmaceutical company Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) with a repeat of its 'buy' recommendation and 30p target price - a significant premium to the current 11p share price.

The American investment bank cites Scancell's successful (and significantly upsized) £11.9 million capital raise as a major source for optimism going forward.

The issue of new stock, at a 10.2% discount to the prevailing market price, extends Scancell's financial runway to mid-to-late 2025.

What management says

19 Sep 2023

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma.

Professor Durrant gives an overview of the findings so far, saying that in the initial 11 patients they have achieved an impressive 82% overall response rate, surpassing the anticipated 70%. This development could be crucial for metastatic melanoma patients, as previous studies reported only a 50% response rate.

She adds that the potential to significantly improve outcomes is especially significant given the rising cases, particularly among young women. While further confirmation is needed in a larger cohort, the data's strength suggests promising results in the broader study.

NanoViricides makes progress as it completes dosing in Phase 1a COVID study

Proactive research analyst John Savin speaks to Stephen Gunnion after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC). The company has successfully completed dosing in a Phase 1a COVID study, marking a major...

on 29/1/24